In the phase III IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score
Jonas Saal, Tobias Bald, M. Hölzel, Manuel Ritter, Peter Brossart, J. Ellinger, N. Klümper
Topics & Concepts
MedicineRenal cell carcinomaSunitinibSorafenibInternal medicineNephrectomyBevacizumabOncologyClear cell renal cell carcinomaSurgeryHepatocellular carcinomaKidneyChemotherapyRenal cell carcinoma treatmentFerroptosis and cancer prognosisBladder and Urothelial Cancer Treatments